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Summary
Objective: Epilepsy is common in individuals with mutations in POLG, the gene
encoding the catalytic subunit of the mitochondrial DNA polymerase gamma.
Early recognition and aggressive seizure management are crucial for patient sur-
vival. Disruption of the blood-brain barrier (BBB) is implicated in various neuro-
logical disorders including epilepsy. The aim of this study was to assess whether
POLG-related disease is associated with BBB dysfunction and what clinical impli-
cations this has for patients.
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Methods: Our retrospective study used data from 83 patients with pathogenic
POLG mutations from 4 countries––Norway, Sweden, Finland, and the United
Kingdom. Data were collected using a structured questionnaire. We used the pres-
ence of raised cerebrospinal fluid (CSF) protein and a raised CSF/serum ratio of
albumin (Q-alb) to evaluate the integrity of the blood-CSF barrier.
Results: Raised CSF protein was found in 70% of patients (n = 58/83) and
appeared to be associated with the most severe phenotypes. In those in whom it
was measured, the Q-alb ratio was markedly elevated (n = 18). The majority of
those with epilepsy (n = 50/66, 76%) had raised CSF protein, and this preceded
seizure debut in 75% (n = 15/20). The median survival time from symptom onset
for those with raised CSF protein was decreased (13 months) compared to those
with normal CSF protein (32 months).
Significance: Our results indicate that there is disruption of the BBB in POLG-
related disease, as evidenced by a raised CSF protein and Q-alb ratio. We also
find that raised CSF protein is a common finding in patients with POLG disease.
Our data suggest that the presence of BBB dysfunction predicts a poorer outcome,
and elevated CSF protein may therefore be an additional biomarker both for early
diagnosis and to identify those at high risk of developing epilepsy.
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1 | INTRODUCTION
Mitochondria perform a number of important functions,
including a major role in energy metabolism. Oxidative
phosphorylation (OXPHOS), the enzyme pathway responsi-
ble for adenosine triphosphate (ATP) production, contains
13 subunits encoded by mitochondrial DNA (mtDNA),
whereas the remaining subunits, together with >1000 other
proteins required for mitochondrial structure and function,
are encoded in the nuclear DNA.1 The diagnosis of mito-
chondrial disorders remains challenging, and currently no
effective treatments exist for the majority of these disorders.
POLG is a nuclear gene that encodes the catalytic sub-
unit of DNA polymerase c, the enzyme responsible for
mtDNA replication and repair.2 Mutations in POLG cause
disease that varies in severity from devastating infantile
phenotypes such as Alpers syndrome and myocerebrohep-
atopathy spectrum (MCHS) to juvenile syndromes compris-
ing epilepsy and ataxia3–5 and to late onset myopathies
with progressive external ophthalmoplegia (PEO).6,7 Epi-
lepsy is particularly common in the early childhood and
juvenile groups3,4,8–10; focal seizures, commonly evolving
into bilateral convulsive seizures,11,12 are the most common
seizure types in both adult and pediatric patients, with
epileptiform discharges predominantly occurring over the
occipital regions.13 The majority of the patients develop
therapy-resistant epilepsy.9,10
The blood-brain barrier (BBB) is formed by a continu-
ous layer of cerebral endothelial cells held together by tight
junctions (Figure 1), separating the blood components from
the brain microenvironment and regulating the entry and
exit of ions, nutrients, macromolecules, and energy metabo-
lites. The BBB is a part of the neurovascular unit that
includes blood vessels, neurons, astrocytes, pericytes, and
microglia, and that is divided into several compartments:
the BBB, the blood–cerebrospinal fluid (CSF) barrier, the
arachnoid barrier, neuroependyma (the fetal-CSF brain bar-
rier), and adult ependyma (free exchange).14 Accumulating
research suggests that disruption of the BBB contributes to
Key Points
• Epilepsy is very common in individuals with
POLG disease and associated with high morbid-
ity and mortality
• Mutations in POLG are associated with progres-
sive disruption of the blood-brain barrier
• Raised CSF protein is commonly seen in patients
with POLG disease, especially in those with sev-
ere phenotypes
• CSF protein can be used as a biomarker to iden-
tify those with high risk of developing epilepsy
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the pathophysiology of various acute and chronic neurolog-
ical disorders (Table 1).15–19
OXPHOS deficiency in central nervous system microvas-
culature, including vascular smooth muscle cell layer and
endothelial cells, has been reported previously.20–22 Evi-
dence of BBB dysfunction, with plasma protein extravasa-
tion, has been suggested by the findings of raised CSF
protein,3 but has only been demonstrated on postmortem
examination in a single patient with POLG disease.22
Given that POLG-related disease causes both a progres-
sive encephalopathy and aggressive epilepsy, the aims of
this study were to investigate whether BBB dysfunction
occurs in POLG disease and, if so, what the consequences
are for affected patients. Our rationale was that greater
understanding of the mechanisms driving POLG-related
disease has the potential to provide us with both new
biomarkers to facilitate earlier diagnosis and novel thera-
peutic targets.
2 | MATERIALS AND METHODS
2.1 | Study design and population
We conducted a multinational, retrospective study of
patients from 9 centers in 4 European countries: Norway
(Haukeland University Hospital, Oslo University Hospital,
St. Olav’s Hospital, and University Hospital of Northern
Norway), the United Kingdom (Great Ormond Street
Hospital), Sweden (Center for Inherited Metabolic Dis-
eases, Karolinska University Hospital and Queen Silvia
Children’s Hospital, University of Gothenburg), and Fin-
land (Children’s Hospital and University Hospital, Helsinki
and Department of Children and Adolescents, Oulu Univer-
sity Hospital). Patients from these centers with pathogenic
POLG mutations were included.
Patients were classified phenotypically into 6 groups,
including (1) Alpers syndrome; (2) MCHS; (3) myoclonic
epilepsy, myopathy, sensory ataxia (MEMSA); (4) ataxia
neuropathy spectrum (ANS); and (5) autosomal dominant
and autosomal recessive progressive external ophthalmople-
gia. Classification was based on previously described crite-
ria.6,23 Patients who did not fulfil the clinical criteria for
the above phenotypes were reported as (6) “other.” The
study cohort as a whole was also classified into 2 groups
according to the presence or absence of epilepsy. Therapy-
resistant epilepsy was defined using the International Lea-
gue against Epilepsy definition.24
Ethical approval was obtained from the Regional Com-
mittee for Medical and Health Research Ethics, Western
Norway (REK 2014/1783-4). Each participating center also
FIGURE 1 Schematic representation of events that we hypothesize are involved in blood-brain barrier (BBB) dysfunction and epilepsy in
individuals with POLG disease. POLG mutations induce a mitochondrial dysfunction that leads to disruption of the BBB tight junctions and
leakage of proteins such as albumin. Uptake of proteins by astrocytes and neurons initiates a cascade of events (downregulation of extracellular
potassium buffering capacity, N-methyl-D-aspartate receptor–mediated neuronal hyperexcitability, and the release of pro-inflammatory cytokines)
that contribute to seizure development
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obtained approval from its local ethical committee. The
study was registered as an audit at Great Ormond Street
Hospital, London, UK.
2.2 | Clinical and laboratory data
Patient’s data were collected using an electronic case report
form. Clinical data included age at onset of symptoms
requiring medical evaluation, detailed medical history, phe-
notype, and survival status or date of last follow-up.
Laboratory data included hepatic aminotransferase,
blood and CSF lactate, muscle respiratory chain enzyme
activities, muscle histology findings, and genetic findings.
CSF protein and/or albumin values at disease onset and
during the disease course were recorded. Because the refer-
ence range for CSF protein may be age dependent, we
have looked at the values according to age,19,25,26 and the
cutoff values used in this study are reported in Table S1.
CSF samples artificially contaminated with blood as a com-
plication of lumbar puncture were not included, and none
of the individuals included in this study had clinical or lab-
oratory evidence of meningitis or encephalitis.
Because albumin is produced exclusively in the liver,
all albumin detected in CSF originates from blood. The
level of CSF albumin provides, therefore, a parameter with
which to evaluate the permeability of the blood-CSF bar-
rier. The ratio of CSF to serum albumin (Q-alb) corrects
for the individual’s albumin level and provides a reflection
of the diffusion gradient of albumin.27,28 This ratio was
calculated as CSF albumin (mg/L)/serum albumin (g/L).
The reference range for Q-alb is age dependent; the cutoffs
used in this study are reported in Table S2.19,27–29
2.3 | Statistical analysis
Data were analyzed using SPSS version 23.0 (Armonk,
NY, USA). Results were considered statistically signifi-
cance with a 2-sided P value of <.05. Survival was defined
by the endpoint—time to death, which was defined as the
interval in months from the onset of symptoms to the date
of death. A comparison of survival time between clinical
categories was performed using log-rank test
(Kaplan-Meier).
3 | RESULTS
3.1 | Demography
Eighty-three patients, (39 male, 44 female) were identified.
Fifty patients were diagnosed in Norway, 19 in Sweden, 9
in the United Kingdom, and 5 in Finland. Median age of
onset for the group as a whole was 9 months (range =
3 weeks to 67 years). The majority of patients were North-
ern European (n = 78), with 3 patients from Iraq and 2
from Cyprus.
3.2 | Phenotype spectrum
Thirty-seven patients fulfilled diagnostic criteria for Alpers,
30 for MEMSA, 8 for ANS, 3 for PEO, 2 for MCHS.
Three patients did not fulfil the diagnostic criteria for the
TABLE 1 Neurological conditions associated with raised CSF
protein and Q-alb ratio
Neurological disorder,
reference
Q-alb ratio 3 103 median
(range)
Multiple sclerosis15
Pattern I 4.8 (3.0-10.8)
Pattern II 7.3 (2.1-33.9)
Pattern III 9.0 (3.3-20.7)
Alzheimer’s16
Early onset 5.4 (4.1-7.7)
Late onset 6.3 (4.9-8.2)
Amyotrophic lateral
sclerosis17
7 (3-15)
Parkinson’s16 7.4 (5.6-10.5)
Viral meningitis18 9.1 (7.2-14.7)
Ischemic stroke19
Territorial 11.1 (7.8-14.4)
Lacunar 9.7 (7.9-18.5)
Guillain-Barre syndrome17 16 (9-55)
Lyme disease18 17.2 (9.7-28.4)
Bacterial meningitis17 18 (6-69)
POLG-related disordersa 21.5 (14.2-56.8)
CSF, cerebrospinal fluid; Q-alb, CSF to serum albumin.
aStudy data.
TABLE 2 Percentages of normal and abnormal CSF total protein
according to POLG-related phenotypes
Phenotype
Abnormal CSF
protein, n (%)
Normal CSF
protein, n (%) Total
Alpers 30 (81%) 7 (19%) 37
MCHS 2 (100%) 0 (0%) 2
MEMSA 20 (67%) 10 (33%) 30
ANS 4 (50%) 4 (50%) 8
PEO 1 (33%) 2 (67%) 3
Other 1 (33%) 2 (67%) 3
Total 58 (70%) 25 (30%) 83
ANS, ataxia neuropathy spectrum; CSF, cerebrospinal fluid; MCHS, myocere-
brohepatopathy spectrum; MEMSA, myoclonic epilepsy, myopathy, sensory
ataxia; PEO, progressive external ophthalmoplegia.
1598 | HIKMAT ET AL.
above phenotypes and were classified as “other” (1 with a
Leigh-like phenotype, 1 with a mitochondrial neurogas-
trointestinal encephalopathy–like phenotype, and 1 with
epilepsy and transient mild elevation in liver function tests;
Table 2).
3.3 | Laboratory findings
Laboratory investigations (Table 3) revealed that 59% (n =
42/71) had elevated serum lactate, 61% (n = 27/54) had
elevated CSF lactate, and 65% (n = 54/82) had elevated
hepatic aminotransferase levels. Muscle biopsy and respira-
tory chain analysis showed that 53% (n = 35/66) had
abnormal histological findings, defined by the presence of
ragged red fibers and/or COX-negative fibers, and 47% (n
= 14/30) had abnormal respiratory chain activities; the
majority (71%, n = 10/14) were in individuals with raised
CSF protein/albumin.
Raised CSF protein and/or albumin was found in 70%
(n = 58/83) at some point during the disease course and
in 65% (n = 48/73) it was present at disease onset.
Seventy-one percent (n = 30/42) had abnormal CSF pro-
tein and/or albumin measured later in the disease course.
The level of CSF protein increased with disease duration;
a median value of 0.83 g/L (range = 0.53-6.00) at disease
onset rose to 1.04 g/L (range 0.74-4.24) later. In 12
patients, longitudinal data showed that CSF protein
increased with time; median CSF protein at onset was
0.94 g/L (range = 0.57-2.5), rising to 1.18 (range = 0.8-
4.2) later in the disease. The frequency of abnormal
elevated CSF protein according to each specific phenotype
is provided in Table 2.
3.4 | CSF protein and epilepsy
Eighty percent (n = 66/83) of the study cohort had epilepsy
(focal onset, focal to bilateral tonic–conic, generalized
onset, myoclonic, epilepsia partialis continua, and status
epilepticus), and in 76% (n = 50/66) of these, CSF protein
was raised regardless of seizure type. Median total CSF
protein for those with status epilepticus was 1.04 g/L
(range = 0.8-2.6). Further analysis showed that 75% (n =
15/20) of those who developed epilepsy later in the disease
course had raised CSF protein at disease onset and that the
majority of those with abnormal raised CSF protein (85%,
n = 45/53) had therapy-resistant epilepsy.
3.5 | Evidence of blood-CSF barrier
dysfunction
Serum albumin and CSF albumin values taken simultane-
ously were available for 18 patients, allowing calculation
of the Q-alb ratio. All cases showed a markedly raised Q-
alb ratio, with median value = 21.5 9 10 3 (range =
14.2 9 103-56.8 9 103).
3.6 | Genetics findings
Pathogenic POLG variants for each case were identified
either by targeted mutation analysis for specific common
mutations (c.1399G>C, p.Ala467Thr and c.2243G>C,
p.Trp748Ser) or by sequence analysis of all coding regions
of POLG. Further analysis showed that there was no clear
association between specific genotype and raised CSF
protein.
3.7 | Survival analysis
Median survival time from symptom onset for those with
normal CSF protein was 32 months, compared to
13 months for those with abnormal CSF protein. Although
not statistically significant (P = .08), Kaplan-Meier curve
analysis showed a clear trend of worse survival for those
with abnormal CSF protein (Figure S1).
4 | DISCUSSION
Our study evaluated the question of whether POLG disease
is associated with BBB dysfunction, as had been suggested
by a previous histological study.22 Using clinical and labo-
ratory data from 83 individuals, we analyzed the frequency
of abnormally raised CSF protein and evaluated the integ-
rity of the brain barrier by measuring the Q-alb ratio.27,28
We found that more than two-thirds of patients (70%) had
raised CSF protein and/or albumin. The Q-alb ratio was
markedly raised in the 18 patients in whom this was mea-
sured (median value = 21.5 9 103), indicating a major
dysfunction in the BBB. When compared with other disor-
ders in which BBB dysfunction occurs, the Q-alb ratio was
among the highest recorded, suggesting that POLG-related
disease profoundly affects BBB integrity (Table 1).
TABLE 3 Major laboratory findings in patients with POLG-
related diseases
Laboratory test Percentage, %
Elevated blood lactate 59% (n = 42/71)
Elevated hepatic aminotransferase 65% (n = 54/82)
Elevated CSF lactate 61% (n = 27/54)
Elevated CSF protein 70% (n = 58/83)
Muscle pathology (RRF, COX) 53% (n = 35/66)
Abnormal RC activities 47% (n = 14/30)
COX, cytochrome oxidase; CSF, cerebrospinal fluid; RC, respiratory chain;
RRF, ragged red fibers.
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Furthermore, our results showed that there was a progres-
sive deterioration in the BBB integrity, as both the propor-
tion of those with abnormal raised CSF protein and the
actual CSF protein value increased with time.
When we compared the proportion of individuals with
abnormal CSF protein and/or albumin to those having
abnormalities of more commonly used biomarkers, we
found that the proportion of those with elevated protein/al-
bumin was higher (Table 3). This suggests that elevated
CSF protein has a higher diagnostic sensitivity for POLG-
related disease than lactate or the other commonly used
biomarkers.
The presence of raised CSF protein was particularly
common in patients with early onset, severe disease pheno-
types (eg, Alpers, MCHS, and MEMSA phenotypes;
Table 2). The median survival time from symptom onset
for those with raised CSF protein was markedly decreased
(13 months) compared to those with normal CSF protein
(32 months). Elevated CSF protein showed a clear associa-
tion with disease severity and with the presence of epi-
lepsy, another major prognostic factor. Our analysis
showed that 76% of POLG patients with epilepsy had
raised CSF protein irrespective of seizure type; that is,
because patients with focal seizures also develop status
epilepticus, it is not possible from our data to assess
whether one seizure type was associated with higher CSF
protein. Interestingly, the presence of elevated CSF protein,
and thus the possibility of BBB dysfunction, preceded the
onset of the seizures (n = 15/20). Our study demonstrates,
therefore, not only the diagnostic relevance of measuring
CSF protein, but also its clinical importance as a biomarker
in the early identification of patients with a high risk of
developing epilepsy.
The relationship between BBB disruption and epilepsy
has been described both in animal models and in
patients.30–34 Large molecular proteins such as albumin that
cross an impaired BBB can be taken up by neurons or
astrocytes; uptake into neurons occurs by unknown mecha-
nisms, but entry into astrocytes is via the TGF-b receptor.35
Uptake is followed by downregulation of extracellular
potassium buffering capacity,36 which facilitates N-methyl-
D-aspartate receptor–mediated neuronal hyperexcitabil-
ity34,37 and the release of pro-inflammatory cyto-
kines.35,38,39 All of these mechanisms may either lead to
seizures or lower the threshold for seizure initiation.30,34,40
In addition, manipulating mitochondrial function in vitro by
inhibition of complex I with rotenone, impairing ATP
production using carbonyl cyanide 4-(trifluoromethoxy)
phenylhydrazone, or inhibiting complex V with oligomy-
cin can also produce rapid changes in BBB permeabil-
ity.41 Furthermore, the same study demonstrated that
inhibition of mitochondrial respiratory chain activity in
mice, by epidural administration of rotenone, impaired
BBB integrity and was associated with marked increase in
BBB permeability.41
Based on our findings and work by others,30,34,35,41 we
suggest a potential mechanism: POLG mutations induce a
mitochondrial dysfunction that leads to disruption of the
BBB tight junctions and leakage of proteins such as albu-
min. Uptake of proteins by astrocytes and neurons initiates
a cascade of events that contribute to seizure development
(Figure 1) and subsequent worsening of the BBB dysfunc-
tion. Furthermore, we believe that the raised CSF protein is
itself evidence of impaired BBB integrity and a valuable
biomarker that can identify those at high risk of developing
epilepsy and, by extrapolation, those with a poor prognosis.
Based on our findings, we recommend that CSF protein
and Q-alb status are measured in all patients presenting
with undiagnosed encephalopathy, and that those with
POLG-related disease with raised CSF protein are
closely monitored with frequent electroencephalographic
recordings to facilitate early recognition and immediate
seizure treatment.
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